Hyperparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hyperparathyroidism markets are expected to exhibit a CAGR of 5.71% during 2024-2034.
The hyperparathyroidism market has been comprehensively analyzed in IMARC's new report titled "Hyperparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperparathyroidism is a medical condition characterized by the overactivity of the parathyroid glands, which are four small glands located in the neck. This disease mainly causes an imbalance in calcium levels due to the excessive production of parathyroid hormone (PTH). The common symptoms associated with the ailment include increased thirst, nausea, vomiting, loss of bone density, constipation, frequent urination, kidney stones, bone and joint pain, persistent fatigue, weakness, etc. In some cases, individuals suffering from this condition may experience changes in their mental health, such as cognitive impairment, memory problems, depression, anxiety, etc. The diagnosis of hyperparathyroidism typically involves a combination of the patient's medical history, clinical characteristics, and physical examination. Blood workups, along with kidney function tests, are also used to measure the levels of calcium, phosphorus, and PTH in the body. The healthcare professional may further conduct nuclear medicine scans, which involve the injection of a radioactive tracer into the overactive parathyroid glands to identify the presence of abnormal tissues. Additionally, a dual-energy X-ray absorptiometry (DXA) scan is recommended to assess the impact of high calcium levels on the bones.
The escalating incidences of benign tumors or adenomas on one of the parathyroid glands, leading to excessive production of PTH, are primarily driving the hyperparathyroidism market. In addition to this, the rising cases of chronic kidney diseases, which can result in diminished activation of vitamin D, reduced calcium absorption, and increased phosphate levels that stimulate the parathyroid glands, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as bisphosphonates, calcimimetics, estrogen replacement therapy, etc., to manage the symptoms of the ailment and decrease the risk of complications is further bolstering the market growth. Apart from this, the inflating application of parathyroidectomy, since it helps to restore the balance of calcium in the body, bringing the levels back within the normal range, is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy to preserve healthy tissues in patients who are unable to undergo surgical removal of the parathyroid glands, is expected to drive the hyperparathyroidism market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperparathyroidism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperparathyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperparathyroidism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperparathyroidism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperparathyroidism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperparathyroidism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperparathyroidism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperparathyroidism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperparathyroidism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with hyperparathyroidism across the seven major markets?
What is the size of the hyperparathyroidism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperparathyroidism?
What will be the growth rate of patients across the seven major markets?
Hyperparathyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperparathyroidism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperparathyroidism market?
What are the key regulatory events related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by status related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by phase related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by route of administration related to the hyperparathyroidism market?
The hyperparathyroidism market has been comprehensively analyzed in IMARC's new report titled "Hyperparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperparathyroidism is a medical condition characterized by the overactivity of the parathyroid glands, which are four small glands located in the neck. This disease mainly causes an imbalance in calcium levels due to the excessive production of parathyroid hormone (PTH). The common symptoms associated with the ailment include increased thirst, nausea, vomiting, loss of bone density, constipation, frequent urination, kidney stones, bone and joint pain, persistent fatigue, weakness, etc. In some cases, individuals suffering from this condition may experience changes in their mental health, such as cognitive impairment, memory problems, depression, anxiety, etc. The diagnosis of hyperparathyroidism typically involves a combination of the patient's medical history, clinical characteristics, and physical examination. Blood workups, along with kidney function tests, are also used to measure the levels of calcium, phosphorus, and PTH in the body. The healthcare professional may further conduct nuclear medicine scans, which involve the injection of a radioactive tracer into the overactive parathyroid glands to identify the presence of abnormal tissues. Additionally, a dual-energy X-ray absorptiometry (DXA) scan is recommended to assess the impact of high calcium levels on the bones.
The escalating incidences of benign tumors or adenomas on one of the parathyroid glands, leading to excessive production of PTH, are primarily driving the hyperparathyroidism market. In addition to this, the rising cases of chronic kidney diseases, which can result in diminished activation of vitamin D, reduced calcium absorption, and increased phosphate levels that stimulate the parathyroid glands, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as bisphosphonates, calcimimetics, estrogen replacement therapy, etc., to manage the symptoms of the ailment and decrease the risk of complications is further bolstering the market growth. Apart from this, the inflating application of parathyroidectomy, since it helps to restore the balance of calcium in the body, bringing the levels back within the normal range, is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy to preserve healthy tissues in patients who are unable to undergo surgical removal of the parathyroid glands, is expected to drive the hyperparathyroidism market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperparathyroidism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperparathyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperparathyroidism market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperparathyroidism market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperparathyroidism market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperparathyroidism marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperparathyroidism market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperparathyroidism market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperparathyroidism market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hyperparathyroidism by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with hyperparathyroidism across the seven major markets?
What is the size of the hyperparathyroidism patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperparathyroidism?
What will be the growth rate of patients across the seven major markets?
Hyperparathyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperparathyroidism drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperparathyroidism market?
What are the key regulatory events related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by status related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by phase related to the hyperparathyroidism market?
What is the structure of clinical trial landscape by route of administration related to the hyperparathyroidism market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERPARATHYROIDISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERPARATHYROIDISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERPARATHYROIDISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERPARATHYROIDISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERPARATHYROIDISM - UNMET NEEDS
10 HYPERPARATHYROIDISM - KEY ENDPOINTS OF TREATMENT
11 HYPERPARATHYROIDISM - MARKETED PRODUCTS
11.1 List of Hyperparathyroidism Marketed Drugs Across the Top 7 Markets
11.1.1 Parsabiv (Etelcalcetide) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Hectorol (Doxercalciferol) - Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zemplar (Paricalcitol) - Abbvie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Sensipar (Cinacalcet) - Amgen/Kirin Holdings Company/Takeda
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rayaldee (Calcifediol) - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERPARATHYROIDISM - PIPELINE DRUGS
12.1 List of Hyperparathyroidism Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HYPERPARATHYROIDISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERPARATHYROIDISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERPARATHYROIDISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperparathyroidism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperparathyroidism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperparathyroidism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperparathyroidism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperparathyroidism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperparathyroidism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperparathyroidism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperparathyroidism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperparathyroidism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperparathyroidism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperparathyroidism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperparathyroidism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperparathyroidism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperparathyroidism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperparathyroidism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperparathyroidism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperparathyroidism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperparathyroidism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperparathyroidism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperparathyroidism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperparathyroidism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperparathyroidism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperparathyroidism - Access and Reimbursement Overview
16 HYPERPARATHYROIDISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERPARATHYROIDISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERPARATHYROIDISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERPARATHYROIDISM - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERPARATHYROIDISM - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERPARATHYROIDISM - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERPARATHYROIDISM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERPARATHYROIDISM - UNMET NEEDS
10 HYPERPARATHYROIDISM - KEY ENDPOINTS OF TREATMENT
11 HYPERPARATHYROIDISM - MARKETED PRODUCTS
11.1 List of Hyperparathyroidism Marketed Drugs Across the Top 7 Markets
11.1.1 Parsabiv (Etelcalcetide) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Hectorol (Doxercalciferol) - Sanofi
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zemplar (Paricalcitol) - Abbvie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Sensipar (Cinacalcet) - Amgen/Kirin Holdings Company/Takeda
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Rayaldee (Calcifediol) - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERPARATHYROIDISM - PIPELINE DRUGS
12.1 List of Hyperparathyroidism Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HYPERPARATHYROIDISM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPERPARATHYROIDISM – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERPARATHYROIDISM - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperparathyroidism - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperparathyroidism - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperparathyroidism - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperparathyroidism - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperparathyroidism - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperparathyroidism - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperparathyroidism - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperparathyroidism - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperparathyroidism - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperparathyroidism - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperparathyroidism - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperparathyroidism - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperparathyroidism - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperparathyroidism - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperparathyroidism - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperparathyroidism - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperparathyroidism - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperparathyroidism - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperparathyroidism - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperparathyroidism - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperparathyroidism - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperparathyroidism - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperparathyroidism - Access and Reimbursement Overview
16 HYPERPARATHYROIDISM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERPARATHYROIDISM MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERPARATHYROIDISM MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
